SCHEMBL2808296

SCHEMBL2808296

c1ccc(CN2CCc3n[nH]c4nc(N5CCN(Cc6ccc7c(c6)OCO7)CC5)nc2c34)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CYP2D6 P10635 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C19 P33261 2/20 0.51
USP2 O75604 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
DRD2 P14416 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
NFKB1 P19838 1/20 0.51
SLC6A2 P23975 1/20 0.51
MAPK1 P28482 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA1A P35348 1/20 0.51
DRD3 P35462 1/20 0.51
HTR2B P41595 1/20 0.51
KCNH2 Q12809 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2816402 0.84 CLPP (0.51) MEN1KMT2ACYP2D6CYP1A2CYP3A4
SCHEMBL2810794 0.84 GAA (0.45) MAPK1TSHRALDH1A1KDM4ELMNA
SCHEMBL2809635 0.82 SIGMAR1 (0.50) MEN1KMT2AMAPK1TSHRALDH1A1
SCHEMBL2814050 0.82 SIGMAR1 (0.50) MEN1KMT2AMAPK1TSHRALDH1A1
SCHEMBL2808212 0.82 SIGMAR1 (0.47) KMT2AMAPK1ALDH1A1KDM4ENPSR1
SCHEMBL2812360 0.81 DRD4 (0.43) DRD2MAPK1DRD3TSHRALDH1A1
SCHEMBL2812035 0.81 POLB (0.47) MEN1KMT2AMAPK1ALDH1A1KDM4E
SCHEMBL13168897 0.81 LMNA (0.41) MEN1KMT2AMAPK1TSHRALDH1A1
SCHEMBL2808367 0.81 CASP1 (0.48) DRD2MAPK1DRD3TSHRALDH1A1
SCHEMBL2809641 0.80 ALDH1A1 (0.44) MEN1KMT2ADRD2DRD3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 MEN1 1767/4885KMT2A 2836/4885CYP2D6 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.